Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

CHMP Favors EU Approval of Keytruda for Advanced Melanoma Patients with Complete Tumor Resection

Source: Immuno-oncology News, December 2018 The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended the approval of Keytruda(pembrolizumab) for the treatment of advanced melanoma patients whose tumor has been completely removed in surgery. The European Commission will now review CHMP’s opinion before making a final decision regarding […]

Skin cancer deaths rates soar, mostly for men: study

Source: Medical Express, December 2018 Skin cancer deaths among men have soared in wealthy nations since 1985, with mortality rates among women rising more slowly or even declining, researchers told a medical conference in Glasgow Sunday. Reasons for the discrepancy between sexes are unclear but evidence suggests men are “less likely to protect themselves from […]

Dr. Hamid on a Retrospective Analysis of Pembrolizumab in Melanoma

Source: OnClive, December 2018 Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses a retrospective analysis of pembrolizumab (Keytruda) in patients with melanoma. A pooled retrospective analysis of patients with metastatic melanoma treated with pembrolizumab on the KEYNOTE-001, -002, and -006 trials was presented at the 2018 ESMO Congress. Hamid says […]

80 GALLONS OF FREE SUNSCREEN DISPENSED AS PUBLIC HEALTH CAMPAIGN WRAPS UP

Source: Santa Monica Mirror, December 2018 By Keldine Hull Sunscreen is a vital part of healthcare, which is why BrightGuard partnered with UCLA and IMPACT Melanoma this year to launch a public health campaign to encourage and support the use of sunscreen. BrightGuard Chief Sales Officer, Vice- President and Co- Founder Alex Beck was a […]